2Solymoss BC, Marcil M, Chaour M, et al. Fasting hyperinsulinism, insulin resistance syndrone, and coronary artery disease in men and women. Am J Cardiol, 1995; 76(16):1152.
3Maria Pyorala, Hiettinen H, Laakso M, et al. Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men.(The 22-years follow-up results of the helsinki policemen study). Circulation, 1998; 98(5):398.
4Goldberg R, Sacks F, Howard B, et al. Diabetic response to pravastatin during the CARE study. Circulation, 1996; 94(suppl I) :1.
5Horio T, Kohno M, Murakawa K, et al. Increased plasma immunoreactive endothelin-1 concentration in hypercholesterolemic rats. Atherosclerosis, 1991 ; 89 : 239.
6Quyyumi AA, Mulcahy D, Andrews NP, et al. Coronary vascular nitric oxide activity in hypertention and hyperrcholesterolemia. Circulation, 1997; 95(1):104.
7Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins implications for cardiovascular event reduction. JAMA,1998; 279(20) ;27.
8Abdelmouttaleb I, Danchin N, Ilaudo C, et aL C-Reactive protein and coronary artery disease; additional evidence of the implication of an inflammatory process in acute coronary syndromes. Am Heart J, 1999; 137(2):346.
9Tuder RM, Groves B,Badesch DB, et al. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension[J]. Am J Pathol, 1994,144 : 275-285.
10Turner NA, O Regan D J, Ball SG, et al. Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing M MP-9 mRNA levels [J]. FASEB J, 2005,19 ( 7 ) : 804-806.
10Nissen SE, Tuzcu EM, Schoenhagen P, et al.. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial [J].JAMA, 2004,291(9): 1071-1080.
